pocketful logo light
pocketful logo light
Orchid Pharma Ltd logo

Orchid Pharma Ltd

NSE: ORCHPHARMA BSE: 524372

₹988.20

(1.48%)

Sat, 19 Sept 2026, 07:15 am

mtf coin illustrationMTF 5x

Company History

1992

  • The company was incorporated on 1st July and obtained the Certificate for Commencement of Business on October 15.
  • The company undertook to set up a 100% EOU for manufacture of cephalosporin group.
  • The company entered into a collaboration agreement with Sintofarm, Italy.

1993

  • The company issued 17,01,800 shares.
  • The company issued 42,98,200 No. of equity shares for cash at par.

1994

  • The company entered into an agreement with SBD Laboratories Italy for technology.
  • The company undertook to expand its combined capacity of cephalexin, cepadroxyl and cefradine.
  • The company allotted 14,73,000 shares to FIIs and domestic corporate bodies.

1996

  • The company proposed to set up a state-of-the-art formulation facility for manufacture of sterile cephalosporin formulations.
  • The company issued 86,73,000 Rights equity shares.

1997

  • The company became the youngest Indian pharmaceutical company to be awarded the ISO 9002 certification.
  • The company tied up with Technology Innovative Industry of Italy.
  • The company launched a range of new products in the steriles category.
  • The company was the country's largest producer of oral and sterile cephalosporins.
  • The company planned to diversify into power generation.
  • The company proposed to establish a modern formulation facility for manufacturing sterile Cephalosporin formulations.
  • The company had a technical collaboration with SBD Laboratories, Italy.

1998

  • Orchid Chemicals and Pharmaceuticals Ltd entered the formulation market.
  • The company received a licence to export sildenafil citrate.
  • The company commissioned its captive power plant.
  • The company received approval from the Drug Controller of India to manufacture and export sildenafil citrate.
  • The company planned to launch its branded version of Pfizer's anti-impotence drug, Viagra, in India.
  • The company decided against acquiring Roussel India's bulk-cum-formulations production facility.
  • The company set up a new plant for non-cephalosporins bulk drugs in Cuddalore.

1999

  • The company launched its initial range of products, including three injectable cephalosporin formulations and two coprescription analgesics.
  • The company proposed to launch a range of cephalosporin antibiotics products.
  • Orchid Chemicals and Pharmaceuticals Ltd tied up with foreign investors for funds to be invested in new technologies and facilities.
  • The company announced an equity issue of 1.06 crore shares at a premium.
  • The company collaborated with JSS College of Pharmacy in research projects to identify active ingredients in traditional herbal medicines.
  • The company considered joining the Indian Pharmaceutical Association.

2000

  • Orchid Chemicals and Pharmaceuticals Ltd signed a memorandum of understanding with Ajanta Pharma Ltd to acquire its bulk drugs manufacturing plant.
  • Orchid launched five new products, including one oral cephalosporin and a dispensible range of select cephalosporin antibiotics.
  • A fire incident occurred in one of the production blocks of Orchid's bulk drug manufacturing facility at Althur.
  • The company was awarded the Trophy for Excellent Performance in Exports as part of the National Export Awards Programme, 1998-99.
  • The company entered into a joint venture with Cambridge Chemicals to distribute its nutraceutical products in the UK.
  • The company set up a new R&D facility to work on new drugs and drug delivery systems at Alathur.

2001

  • Orchid Chemicals & Pharmaceuticals issued foreign currency convertible bonds to International Finance Corporation for $20m.
  • Orchid Chemicals & Pharmaceuticals proposed to expand the strength of its board to 15.

2002

  • Narayana Reddy resigned from the Board of Orchid Chemicals & Pharma.
  • Orchid Chemicals & Pharmaceuticals inked a 50:50 joint venture alliance pact with Bexel Biotechnology Inc.
  • Orchid Chemicals & Pharmaceuticals announced the induction of Mr RS Prasad as the Executive Director and Chief Operating Officer of Orchid Healthcare.
  • IDBI withdrew the nomination of Shri S Gajendran and appointed Shri M V Badrinath as its nominee on the Board.

2003

  • Mr A R Hedge relinquished his directorship in Orchid.
  • Orchid acquired Mano Pharmaceuticals for a consideration of Rs 26cr.
  • Orchid received formal approval from the US Food and Drug Administration for Cephalaxin.
  • Orchid entered into a new co-marketing concept and signed an agreement with 4 companies.
  • Orchid Chemicals Aurangabad facility was awarded ISO 14001 and OHSAS 18001.

2004

  • Orchid got Europe drug authority nod.
  • Orchid Chemicals & Pharmaceuticals was granted CoS for Cefotaxime Sodium.
  • Orchid inked a pact with Par Pharmaceuticals Inc to market oral cephalosporin formulations in the US market.
  • Orchid Chemicals & Pharmaceuticals forged an alliance with US-based Par Pharmaceuticals.
  • Orchid entered into an agreement with Apotex Inc for an exclusive marketing pact in the Canadian market.
  • Orchid was granted the Certificate of Suitability by the European Directorate for the Quality of Medicines for its API product Cephradine.
  • Orchid Chem entered the US market.

2005

  • Orchid entered into a pact with Alpharma Inc to market oral non-antibiotic formulations in US and European markets.
  • Orchid entered into an agreement with STADA Pharmaceuticals, Inc.
  • Orchid Chemicals & Pharmaceuticals received approval from USFDA for generic Ceftriaxone ANDA.
  • Orchid Chemicals & Pharmaceuticals gave a bonus in the ratio of 1:2.

2006

  • Orchid signed a deal with Biovitrum in the drug discovery field.

2008

  • Orchid Chemicals & Pharmaceuticals received approval from the US FDA for its ANDA for Cefuroxime Axetil Tablets.
  • Orchid Chemicals and Pharmaceuticals Ltd and Merck & Co entered into a research collaboration and licence agreement.

2009

  • Orchid Chemicals & Pharmaceuticals received approval from the US FDA for its ANDAs for Piperacillin and Tazobactam for injection.

2010

  • Orchid collaborated with Alvogen to license and market its eight oral non-antibiotic generic formulations.
  • Orchid acquired US-based marketing company Karalex Pharma.
  • Orchid redeemed FCCBs aggregating to USD 25.69 million.

2011

  • Orchid's API Manufacturing facility at Alathur was awarded OHSAS 18000 : 2007 certification.
  • Orchid's drug discovery research initiative with Merck advanced.

2012

  • Orchid Pharma reported the successful completion of Phase I study of its novel PDE4 inhibitor molecule, OCID 2987.
  • Orchid Pharma entered into an agreement to transfer its Penicillin & Penem API business and its API facilities in Aurangabad to Hospira for approximately US$ 200 million.

2013

  • Orchid entered into a strategic partnership with Allecra Therapeutics for the development of novel antibiotics.

2014

  • Orchid received US FDA approval for Eszopiclone Tablets ANDA.

2015

  • The company received approval from the US FDA for the Abbreviated New Drug Application.
  • The company changed its name from Orchid Chemicals & Pharmaceuticals Ltd to Orchid Pharma Ltd.
  • The trading symbol of the company changed from ORCHIDCHEM to ORCHIDPHAR.

2016

  • Orchid received final USFDA approval for Rasagiline generic formulation.

2022

  • Orchid Pharma Limited launched a Qualified Institutional Placement programme of INR 500 Crore.

2023

  • Orchid Bio Pharma was granted approval by the Competent Authority under the Production Linked Incentive Scheme for manufacturing of product 7 ACA.

2024

  • The company Board of Directors informed about the Scheme of Amalgamation of Dhanuka Laboratories Limited with Orchid Pharma Limited under Regulation SEBI.

Open Your Free Demat Account

Enter your phone number